--- title: "Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia" type: "News" locale: "en" url: "https://longbridge.com/en/news/292027470.md" description: "A recent study revealed that delivering the MMUT gene through ISLV resulted in long-lasting therapeutic effects in mice. The gene transfer was successful in more than 80% of the liver cells. Genespire is moving forward with its primary treatment for MMA, GENE202, aiming to bring it to clinical trials. The development took place in MILAN on July 8, 2026." datetime: "2026-07-08T07:01:19.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292027470.md) - [en](https://longbridge.com/en/news/292027470.md) - [zh-HK](https://longbridge.com/zh-HK/news/292027470.md) generator: "portal-rs" --- # Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia A recent study revealed that delivering the MMUT gene through ISLV resulted in long-lasting therapeutic effects in mice. The gene transfer was successful in more than 80% of the liver cells. Genespire is moving forward with its primary treatment for MMA, GENE202, aiming to bring it to clinical trials. The development took place in MILAN on July 8, 2026. ## Related News & Research - [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md) - [Genetix kicks off sickle cell disease awareness campaign](https://longbridge.com/en/news/296468544.md) - [Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301](https://longbridge.com/en/news/296321067.md) - [Oncoinvent publishes corporate presentation on Radspherin alpha therapy for peritoneal metastases](https://longbridge.com/en/news/296475294.md) - [Realheart targets February 2028 readiness for first-in-human implant of total artificial heart](https://longbridge.com/en/news/296444895.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**